AstraZeneca’s AZD7442 antibody cocktail was less effective than the company expected.
This is evidenced by the results of the study.
According to scientists, the antibody cocktail prevented the appearance of COVID-19 coronavirus symptoms in only 33% of cases. The study was conducted on unvaccinated participants over the age of 18 who had come into contact with infected people. Two of the three subjects received antibodies and the rest received a placebo.
“The study did not reach the primary endpoint of post-exposure prophylaxis of symptomatic COVID-19 with AZD7442 compared with placebo,” the statement said.
According to the results, there were 23 cases of symptomatic infection in the group that received the antibody and 17 cases in the placebo group.
“AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% compared with placebo, which was not statistically significant,” the researchers added.